Centre for Haemophilia and Thrombosis, Aarhus University Hospital, Skejby, Denmark.
Anesthesiology. 2011 Aug;115(2):294-302. doi: 10.1097/ALN.0b013e318220755c.
Thromboelastography/metry (TEG®; Haemoscope, Niles, IL/ROTEM®; Tem International GmbH, Munich, Germany) is increasingly used to guide transfusion therapy. This study investigated the diagnostic performance and therapeutic consequence of using kaolin-activated whole blood compared with a panel of specific TEM®-reagents to distinguish: dilutional coagulopathy, thrombocytopenia, hyperfibrinolysis, and heparinization.
Blood was drawn from 11 healthy volunteers. Dilutional coagulopathy was generated by 50% dilution with hydroxyethyl starch 130/0.4 whereas thrombocytopenia (mean platelet count 20 ×10⁹/l) was induced using a validated model. Hyperfibrinolysis and heparin contamination were generated by tissue plasminogen activator 2 nM and unfractionated heparin 0.1U/ml, respectively. Coagulation tests were run on ROTEM® delta.
Kaolin-activated whole blood showed no differences between dilutional coagulopathy and thrombocytopenia (mean clotting time 450 s vs. 516 s, α-angle 47.1° vs. 41.5°, maximum clot firmness 35.0 mm vs. 34.2 mm, all P values ≥0.14). Hyperfibrinolysis specifically disclosed an increased maximum lysis (median: 100%, all P values less than 0.001), and heparin induced a distinctly prolonged clotting time (2283 s, all P values less than 0.02). The coagulopathies were readily distinguishable using a panel of TEM-reagents. In particular, dilutional coagulopathy was separated from thrombocytopenia using FIBTEM (maximum clot firmness 1.9 mm vs. 11.2 mm, P < 0.001). The run time of analysis to achieve diagnostic data was shorter applying a panel of TEM-reagents. A transfusion algorithm based on kaolin suggested platelets in case of dilutional coagulopathy, whereas an algorithm applying TEM-reagents suggested fibrinogen.
Monoanalysis with kaolin was unable to distinguish coagulopathies caused by dilution from that of thrombocytopenia. Algorithms based on the use of kaolin may lead to unnecessary transfusion with platelets, whereas the application of TEM-reagents may result in goal-directed fibrinogen substitution.
血栓弹力描记术/测量法(TEG®;Haemoscope,Niles,IL/ROTEM®;Tem International GmbH,慕尼黑,德国)越来越多地用于指导输血治疗。本研究旨在使用高岭土激活全血与特定 TEM®试剂组合来区分稀释性凝血障碍、血小板减少症、纤维蛋白溶解亢进和肝素化,并评估其诊断性能和治疗效果。
从 11 名健康志愿者中抽取血液。通过 50%羟乙基淀粉 130/0.4 稀释生成稀释性凝血障碍,使用经验证的模型诱导血小板减少症(平均血小板计数 20×10⁹/L)。使用组织型纤溶酶原激活物 2nM 和未分级肝素 0.1U/ml 分别生成纤维蛋白溶解亢进和肝素污染。凝血试验在 ROTEM® delta 上进行。
高岭土激活全血在稀释性凝血障碍和血小板减少症之间无差异(凝血时间分别为 450s 和 516s,α 角分别为 47.1°和 41.5°,最大凝块硬度分别为 35.0mm 和 34.2mm,所有 P 值均≥0.14)。纤维蛋白溶解亢进特异地显示出增加的最大溶解(中位数:100%,所有 P 值均小于 0.001),肝素引起明显延长的凝血时间(2283s,所有 P 值均小于 0.02)。使用 TEM 试剂组合可轻松区分凝血障碍。特别是,FIBTEM 将稀释性凝血障碍与血小板减少症区分开来(最大凝块硬度分别为 1.9mm 和 11.2mm,P<0.001)。应用 TEM 试剂组合分析的运行时间更短,可更快获得诊断数据。基于高岭土的输血算法建议在发生稀释性凝血障碍时输注血小板,而基于 TEM 试剂的算法则建议输注纤维蛋白原。
单独使用高岭土无法区分稀释性凝血障碍和血小板减少症引起的凝血障碍。基于高岭土使用的算法可能导致不必要的血小板输注,而应用 TEM 试剂可能导致有针对性的纤维蛋白原替代。